Libby Tiffany J, Fleming Kirsten, Amin Bijal
Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York.
Division of Dermatology, Montefiore Medical Center, Bronx, New York.
J Cutan Pathol. 2019 Apr;46(4):290-292. doi: 10.1111/cup.13418. Epub 2019 Feb 19.
Histiocytoid Sweet syndrome (HSS) is a rare histopathologic variant of Sweet syndrome that demonstrates dermal and/or subcutaneous infiltrate with a prominent component of myeloid cells resembling histiocytes. It has been known to occur in association with hematologic neoplasms, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia, but whether it confers an increased risk of such neoplasms is controversial. Here, we describe a case of a HSS that led to the diagnosis of MDS with an isocitrate dehydrogenase 1 (IDH-1) mutation and a corresponding study looking for additional cases of IDH-1 mutations in biopsies of histiocytoid and conventional Sweet syndrome.
组织细胞样Sweet综合征(HSS)是Sweet综合征一种罕见的组织病理学变异型,表现为真皮和/或皮下有以类似组织细胞的髓样细胞为主的浸润。已知其与血液系统肿瘤相关,包括骨髓增生异常综合征(MDS)和急性髓系白血病,但它是否会增加此类肿瘤的发病风险仍存在争议。在此,我们报告1例导致诊断为伴有异柠檬酸脱氢酶1(IDH-1)突变的MDS的HSS病例,并进行了一项相应研究,以在组织细胞样Sweet综合征和传统Sweet综合征活检标本中寻找更多IDH-1突变病例。